Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Reexamination Certificate
2006-09-05
2006-09-05
Mosher, Mary E. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
C435S235100
Reexamination Certificate
active
07101561
ABSTRACT:
The present invention relates to a method for purifying recombinant HCV single or specific oligomeric envelope proteins selected from the group consisting of E1 and/or E2 and/or E1/E2, characterized in that upon lysing the transformed host cells to isolate the recombinantly expressed protein a disulphide bond cleavage or reduction step is carried out with a disulphide bond cleavage agent. The present invention also relates to a composition isolated by such a method. The present invention also relates to the diagnostic and therapeutic application of these compositions. Furthermore, the invention relates to the use of HCV E1 protein and peptides for prognosing and monitoring the clinical effectiveness and/or clinical outcome of HCV treatment.
REFERENCES:
patent: 4395395 (1983-07-01), Tabor et al.
patent: 5308750 (1994-05-01), Mehta et al.
patent: 5514539 (1996-05-01), Bukh et al.
patent: 5610009 (1997-03-01), Watanabe et al.
patent: 5830691 (1998-11-01), Miyamura et al.
patent: 5871962 (1999-02-01), Bukh et al.
patent: 5919454 (1999-07-01), Brechot et al.
patent: 5942234 (1999-08-01), Ralston et al.
patent: 6150134 (2000-11-01), Maertens et al.
patent: 6613333 (2003-09-01), Leroux-Roels et al.
patent: 6635257 (2003-10-01), Depla et al.
patent: 199957127 (2000-02-01), None
patent: WO 92/08734 (1992-05-01), None
patent: WO 93/02103 (1993-02-01), None
patent: WO 93/04205 (1993-03-01), None
patent: WO 93/15193 (1993-08-01), None
patent: WO 95/12677 (1995-05-01), None
patent: WO 93 04385 (1996-02-01), None
patent: WO 96/04385 (1996-02-01), None
patent: WO 96/13590 (1996-05-01), None
patent: WO 98 21338 (1998-05-01), None
patent: WO 98/21338 (1998-05-01), None
patent: WO 99/67285 (1999-12-01), None
patent: WO 03/51912 (2003-06-01), None
Forns et al. Journal of Hepatology 37:684-695, 2002.
Forns et al (Journal of Hepatology 37:684-695, 2003).
Houghton et al (Prospects for Prophlactic and Therapeutic Hepatitis C Vaccines, Princess Takamatsu Symp. 25:237-243,1995).
Song et al, Journal of Virology, vol. 74, No. 6, Mar. 2000, pp 2920-2925.
Lopez-Diaz de Cerio et al, International Immunology, vol. 11, No. 12, 1999, pp 2025-2033.
Saito et al, Gastroenterology, vol. 112, 1997, pp 1321-1330.
Lee et al, Journal of Virology, vol. 73, No. 1, Jan. 1999, pp 11-18.
Esumi et al, Arch. Virol, vol. 144, 1999, pp 973-980.
Heile et al, Journal of Virology, vol. 74, No. 15, Aug. 2000, pp 6885-6892.
Seong et al, Virus Research, vol. 55, 1998, pp 177-185.
Howard et al, Developments in Biological Standardization, vol. 92, 1998, pp 157-162.
Leroux-Roels et al, Hepatology, American Association for the Study of Liver Diseases, 2001.
Nevens et al, Hepatology, A Pilot Study of Therapeutic Vaccination . . . With Chronic Hepatitis C, Nov. 2003, pp 1289-1296.
Pawlotsky et al, Hepatology, Hepatitis C. Development of New Drugs and Clinical Trials: Promises and Pitfalls, Vo. 39, No. 2, 2004, pp 554-567.
Botarelli et al, Gastroenterology, T-Lymphocyte Response to Hepatitis C. Virus in Different Clinical Courses of Infection, 1993; 104:580-587.
Major et al, Journal of Virology, Previously Infected and Recovered Chimpanzees Exhibit Rapid Responses that Control Hepatitis C Virus Replication Upon Rechallenge, 2002, p 6586-6595, vol. 76, No. 13.
Bassett et al, Hepatology, Protective Immune Response to Hepatitis C Virus in Chimpanzees Rechallenged Following Clearance of Primary Infection, Jun. 2001, pp 1479-1487.
Weiner et al, Journal of Virology, Intrahepatic Genetic Inoculation of Hepatitis C. Virus RNA Confers Cross-Protective Immunity, Aug. 2001, pp 7142-7148, vol. 75, No. 15.
Mehta et al, Lancet, Protection Against Persistence of Hepatitis C, vol. 359, Apr. 27, 2002, pp 1478-1483.
Bosman et al, Hepatology, 1997, 26(4) 412A.
Large et al, The Journal of Immunology, 1999, 162:931-938.
Houghton et al., (1995) Prospects for prophylactic and therapeutic hepatitis C virus vaccines. Princess Takamatsu Symp 25, 237-243.
Houghton et al., (1997) Development of an HCV vaccine. In: Viral Hepatitis and Liver Disease (Rizetto, Purcell, Gerin, Verme, eds), Edizioni Minerva Medica (Turin, Italy), pp. 656-659.
Large et al., (1999) Suppression of Host Immune Response by the Core Protein of Hepatitis C Virus: Possible Implications for Hepatitis C Virus Persistence, The American Association of Immunologies, pp. 931-938.
Choo et al, “Vaccination of Chimpanzees Against . . . Hepatitis C Virus”, Proc. Natl. Acad. Sci., 1994, pp. 1294-1298.
Lanford et al, “Analysis of Hepatitis C Virus . . . ”, Virology 197, pp. 225-235, 1993.
Nishihara et al, “Secretion and Purification of Hepatitis C . . . ”, Gene 129; 207-214, 1993.
Ralston et al, “Characterization of Hepatitis C Virus . . . ”, J. Virol 67:6753-6761, 1993.
Bosman F et al.: Purification of the hepatitis C virus envelope proteins and analysis of their oligomeric state. 48th Annual Meeting of the American Association for the Study of Liver Disease, Chicago, Illinois, USA, Nov. 7-11, 1997. Hepatology 26 (4 Part 2). 1997. 412A, XP002087226 sse abstract 1136.
Ristoni et al, Compositional bias and mimicry toward the nonself proteome in immunodominant T cell epitopes of self and nonself antigens. FASEB (2000) vol. 14, No. 3, pp. 431-438.
Paul, Fundamental Immunology, Raven Press, New York, NY 1993, 3rdEdition, p. 251, col. 1, lines 11-12.
Baumert et al, Hepatisis C virus structural proteins assemble into virus like particles in insect cells. Journal of Virology (May 1998) vol. 72, No. 5. pp. 3827-3836.
Bosman Fons
Depla Erik
Maertens Geert
Innogenetics N.V.
Mosher Mary E.
Nixon & Vanderhye P.C.
LandOfFree
Purified hepatitis C virus envelope proteins for diagnostic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Purified hepatitis C virus envelope proteins for diagnostic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Purified hepatitis C virus envelope proteins for diagnostic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3597776